DOI: https://doi.org/10.22141/2224-0713.1.79.2016.73991

Practical Aspects of Memantin Use for the Treatment of Alzheimer Dementia

V.A. Kholin, N.Yu. Bachinskaya

Abstract


The paper is devoted to the questions of help to the patients with dementia. Nowadays two basic groups of agents for the routine drug treatment of dementia are available, namely acetyl cholinesterase inhibitors and NMDA antagonists (N-methyl-D-aspartate). Mementin belongs to the last group. Memantin is recommended as a medication for the treatment of Alzheimer disease by European Medicines Agency (ЕМЕА) and American Federal Drug Administration (US FDA). The paper considers the recommendations on dosage and schemes or memantin use, description of psychometric scales and assessment instruments specific for dementia and Alzheimer disease that allow estimate therapy efficiency going beyond subjective perception to the level of standard and unify complex assessment.

Keywords


dementia; Alzheimer disease; memantin; psychometric scales.

References


Andrieu S. et al. Methodological issues in primary prevention trials for neurode-generative dementia // J. Alzheimers Dis. — 2009. — 16(2). — 235-70.

Burns A., O`Brien J., BAP Dementia Consensus Group, et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology // J. Psychopharmacol. — 2006. — 20. — 732-55.

NICE technology appraisal January 18, 2011. Azheimer’s disease — donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination.

Aarsland D. et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial // Lancet Neurol. — 2009. — 8(7). — 613-8.

Emre M. et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial // Lancet Neurol. — 2010. — 9(10). — 969-77.

Jones R.W. et al. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in mo-derate to severe AlzheimerÕs disease // Int. J. Geriatr. Psychiatry. — 2007. — 22. — 258-62.

Бачинська Н.Ю. Ефективність лікування донепезилу гідрохлоридом хворих похилого віку із синдромом деменції альцгеймерівського і судинного типу залежно від поліморфізму гена апоЕ / Н.Ю. Бачинська, І.Ф. Рожелюк, В.О. Холін, І.М. Пішель, Ю.І. Леонов // Український неврологічний журнал. — 2014. — № 1. — С. 107-115.

Borson S. et al. The Mini-Cog: a cognitive «vital signs» measure for dementia screening in multi-lingual elderly // Int. J. Geriatr. Psychiatry. — 2000. — 15(11). — 1021-7.

Borson S. et al. Improving identification of cognitive impairment in primary care // Int. J. Geriatr. Psychiatry. — 2006. — 21(4). — 349-55.

Інструкція для медичного застосування препарату Мемокс, РП № UA/13188/01/01, UA/13188/01/02, наказ МОЗ України № 752, дата останнього перегляду 01.09.2015 р. // http://drlz.kiev.ua.

Wilcock G.K. et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies // J. Clin. Psychiatry. — 2008. — 69(3). — 341-8.

Borson S. et al. The Mini-Cog as a screen for dementia: validation in a population-based sample // J. Am. Geriatr. Soc. — 2003. — 51(10). — 1451-4.

Tombaugh T.N. Test-retest reliable coefficients and 5-year change scores for the MMSE and 3MS // Archives of Clinical Neuropsychology. — 2005. — 20. — 485-503.

Информация в открытом доступе: http://www.mocatest.org/about/ — дата последнего доступа к ссылке 21.02.2016 г.

Rosen W.G. et al. A new rating scale for Alzheimer’s disease. AND National Institute on Aging. Alzheimer’s Disease Assessment Scale-Cognitive Subscale // Am. J. Psychiatry. — 1984. — 141(11). — 1356-64.

Информация в открытом доступе: http://www.dementia-assessment.com.au/behavioural/ — дата последнего доступа 21.02.2016 г.

Bourne P.A. Activities of daily living, instrumental activities for daily living and predictors of functional capacity of older men in Jamaica // N. Am. J. Med. Sci. — 2009. — 1(4). — 184-92.

Wilcock G.K., Ballard C.G., Cooper J.A. et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies // J. Clin. Psychiatry. — 2008.

Boinpally R. et al. A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer’s Disease: Two Phase I Studies in Healthy Volunteers // Clin. Drug. Investig. — 2015. — 35(7). — 427-35.




Copyright (c) 2016 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта